Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Impetigo and ecthyma

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Synopsis

Distinguish superficial impetigo from deeper ulcerative ecthyma and important blistering mimics, use hygiene and finite antimicrobial treatment proportionately, and investigate non-response or recurrence.

  • Non-bullous impetigo begins with thin-roofed vesicles or pustules that become honey-coloured crusted erosions, commonly around the nose, mouth and exposed limbs.
  • Bullous impetigo produces larger flaccid blisters, often on trunk or flexures, and warrants oral treatment because toxin-producing staphylococci are involved.
  • Ecthyma has an adherent dark crust over a punched-out ulcer extending into dermis; swab and use systemic treatment rather than treating it as a superficial spot.
  • For localised non-bullous impetigo, NICE first offers hydrogen peroxide 1% cream; a short topical antibiotic is reserved when that is unsuitable or ineffective.
  • Use oral flucloxacillin for bullous disease, widespread non-bullous disease when oral treatment is selected, or systemic illness; do not combine topical and oral antibiotics routinely.
  • A five-day course is standard, extended to seven days according to severity and response; an unreviewed repeat is not an acceptable substitute for sampling.
  • Advise hand hygiene, short nails, avoidance of scratching, no sharing towels or face cloths, and exclusion from school or work until lesions are crusted and healed or 48 hours after antibiotics begin.
  • Swab worsening, non-responsive or recurrent disease and reconsider herpes, eczema, resistance, scabies and deeper infection before changing antibiotics.

Key red flags

Systemic toxicity, rapidly spreading pain or erythema, extensive bullae, mucosal involvement, periorbital disease, immunocompromise, neonatal infection, dehydration or suspected staphylococcal scalded-skin syndrome requires urgent assessment.

Invasive extension

Rapidly expanding warmth, swelling and pain beyond lesions, fever or physiological instability indicates cellulitis or sepsis and needs urgent care.

Scalded-skin warning

Diffuse tenderness, fever, superficial exfoliation and widespread positive Nikolsky sign, especially in a child, suggests staphylococcal scalded-skin syndrome.

Investigation priorities

01
Clinical morphology and extent assessmentFirst step

Classify non-bullous, bullous, ecthyma or invasive disease and choose treatment route.

Management branches

Localised non-bullousMinimise antimicrobial exposure

A small area of superficial honey-crusted lesions occurs without bullae, systemic illness or high complication risk.

  1. Offer hydrogen peroxide 1% cream two or three times daily for five days and explain local irritation and eye avoidance.
  2. If unsuitable or ineffective, choose a five-day topical antibiotic according to NICE and local resistance, rather than combining products.
  3. Review spread or non-response, swab when indicated and escalate to oral treatment only when extent, depth or systemic state justifies it.

Key medicines

Hydrogen peroxide 1% creamApply two or three times daily for five days to localised non-bullous impetigo, avoiding eyes and mucosa.Can bleach hair and fabrics and irritate skin; unsuitable around eyes, and evidence in people with darker skin is limited.
Fusidic acid 2% creamApply three times daily for five days when hydrogen peroxide is unsuitable or ineffective; extend to seven days only by clinical judgement.Resistance can develop rapidly; avoid repeated or widespread use, do not combine with oral antibiotics routinely and follow local susceptibility advice.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG153 Impetigo antimicrobial prescribingTopical and oral selection, exact courses, review, culture and recurrence advice.
  • NHS impetigoRecognition, contagious period, hygiene and patient safety-netting.
  • DermNet ecthymaDepth, ulcer morphology, host factors and scarring.
  • Fucidin cream SmPCFusidic acid application and safety information.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom